Breast tumors that are ER and PR positive are treated with target hormone therapy, such as tamoxifen and an aromatase inhibitor, while HER2-positive breast cancer is treated with a monoclonal antibody drug, trastuzumab [11]. This evidence concerns the gene ESR1 and breast carcinoma.